Docoh
Loading...

XENE Xenon Pharmaceuticals

News

From Benzinga Pro
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
12 Jan 22
Biotech, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory milestone,
Xenon Pharma Reports Collab With Neurocrine Biosciences To Develop Treatments For Epilepsy Reached Regulatory Milestone, Triggering $15M Payment To Xenon
12 Jan 22
Biotech, News, FDA, General
Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (NASDAQ:NBIX) achieved
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
29 Dec 21
Analyst Color, Biotech, Small Cap, Analyst Ratings, Trading Ideas, General
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior vice president of biotech equity research at the analyst firm, said she attributes the underperformance to a few factors.
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
3 Dec 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
3 Dec 21
Biotech, News, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Xenone Pharma Highlights Presentation Of Added Positive Data From Phase 2b 'X-TOLE' Trial At Annual Meeting Of American Epilepsy Society: Data Showed All Primary, Secondary Endpoint Reductions Were Statistically Significant
3 Dec 21
Biotech, News, FDA, General
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Results from New Sub-Analyses
Xenon Pharma Offers Update On Its Neurology Programs At Annual Meeting Of American Epilepsy Society
3 Dec 21
Biotech, News, FDA, Events, General
Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
28 Nov 21
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-shortened week.
SVB Leerink Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $40
11 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Marc Goodman maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $34 to $40.
Xenon Pharmaceuticals Q3 EPS $(0.36) Beats $(0.38) Estimate, Sales $8.12M Miss $10.22M Estimate
10 Nov 21
Earnings, News
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.38) by 5.26 percent. This is a 44 percent decrease over losses of $(0.25) per share from
Earnings Scheduled For November 10, 2021
10 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
28 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
RBC Capital Initiates Coverage On Xenon Pharmaceuticals with Outperform Rating, Announces Price Target of $43
28 Oct 21
News, Price Target, Initiation, Analyst Ratings
RBC Capital analyst Brian Abrahams initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating and announces Price Target of $43.

Press releases

From Benzinga Pro
Thinking about buying stock in Xenon Pharmaceuticals, Maxeon Solar Technologies, Aurora Mobile, XpresSpa Group, or Dare Bioscience?
3 Dec 21
Opinion, Press Releases
NEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XENE, MAXN, JG, XSPA, and DARE.
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b 'X-TOLE' Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
3 Dec 21
Health Care, Press Releases
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups Results from New Sub-Analyses
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)
3 Dec 21
News, Press Releases
BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary,
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
12 Nov 21
News, Press Releases
BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon's President and Chief
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 Nov 21
Earnings, News, Press Releases
XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Xenon
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update
3 Nov 21
News, Press Releases
BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and